Trial
NCT03709576
Pevonedistat and Azacitidine as Maintenance Therapy After Allogeneic Stem Cell Transplantation for Non-Remission AML
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Milton S. Hershey Medical Center
Collaborators
Millennium Pharmaceuticals, Inc.; Takeda
Condition
Acute Myeloid Leukemia (AML)
Intervention
Pevonedistat
Why stopped
Funding pulled
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-12-16